Chronic kidney disease definition and classification: the quest for refinements  by Eknoyan, G.
Kidney International (2007) 72       1183
commentar y
mutation in another gene for nephrosis to 
manifest. Basic-science approaches provide 
an important means of identifying these 
potential genetic candidates and conse-
quent accurate functional characterization 
of the encoded protein in the context of its 
cellular environment. Moreover, these key 
scientiﬁc building blocks ultimately lead 
to a uniquely focused approach able to 
identify those populations most at risk of 
glomerular disease and the development of 
directed strategies to ameliorate that risk.
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Chronic kidney disease definition 
and classification: the quest for 
refinements
G Eknoyan1
The definition and staging of chronic kidney disease (CKD) have 
provided a unifying approach to CKD that has generated considerable 
new information on the epidemiology, course, outcomes, and 
burden of CKD.  Eriksen and Ingebretsen5 propose a change in the 
current 3 months chronicity criterion of CKD. Whereas longer lengths 
of chronicity changed the number of patients in stages 3 and 4, 
mortality remained high in each of their new groupings.  Essentially, 
CKD persisted and remained a risk multiplier of death.  
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Beginning with Richard Bright’s report of 
cases with end-stage kidneys, and certainly 
after the advent of maintenance dialysis in 
the 1960s, much of the attention of neph-
rology and health agencies focused on 
the cost and treatment of end-stage renal 
disease (ESRD). As data from dialysis reg-
istries accrued in the 1980s, it gradually 
became evident that the mortality of these 
patients was high, principally because of 
coexistent morbidities and the complica-
tions of kidney disease with which they 
presented to dialysis, and that their care 
should have been initiated earlier.
Throughout this period, and well into 
the 1990s, kidney disease was categorized 
by cause (glomerulonephritis, pyelone-
phritis, lupus nephropathy, and so on). 
This traditional taxonomic approach is 
useful when diagnosis determines treat-
ment of a speciﬁc disease. What registry 
data revealed, however, was that most 
ESRD patients presented in kidney failure 
without a previous diagnosis of kidney 
disease, and that the number of cases of 
kidney failure that could be attributed to 
traditional causes was relatively small 
and decreasing, whereas the number due 
to hypertension and diabetes was large 
and increasing, especially in the elderly 
and some ethnic and racial groups. In the 
majority of them, the kidney disease had 
been asymptomatic and escaped detec-
tion, and the complications of the dis-
ease had been established. The question 
of how to identify them early enough to 
treat them became a major concern but 
remained unanswered.
As epidemiologic data on kidney dis-
ease accrued in the 1990s, it became 
evident that the systemic complications 
of progressive loss of kidney function 
(anemia, hypertension, mineral and 
bone disorders, cardiovascular disease) 
were uniform and independent of the 
primary cause of the kidney disease. 
The various terms used to describe the 
commonality of these patients (chronic 
renal failure, pre-dialysis, pre-ESRD, 
azotemic, uremic) were descriptive, ill-
deﬁned, vague, and variably used. This 
ambiguous terminology coupled with 
categorization of patients at diﬀering 
cutoﬀ levels of creatinine resulted in 
data that indicated a large, but variable, 
number of individuals with kidney dis-
ease in the general population.1
In 2002, the National Kidney Founda-
tion’s Kidney Disease Outcomes Qual-
ity Initiative (KDOQI) clinical practice 
guidelines provided for the ﬁrst time 
a working definition of chronic kid-
ney disease (CKD), irrespective of the 
cause of kidney disease, based on the 
presence of either kidney damage or a 
glomerular ﬁltration rate of less than 
60 ml/min/1.73 m2 for more than 3 
months. The guidelines also proposed 
a classiﬁcation system based on sever-
ity determined by the level of kidney 
function, calculated from the estimated 
glomerular ﬁltration rate (eGFR), again 
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irrespective of the etiology of kidney 
disease. Using then available data-
bases, the guidelines documented the 
increased number of complications, 
morbidity, and mortality associated with 
declining eGFR and provided estimates 
of the prevalence of CKD based on the 
new classiﬁcation.2
T h e  K D O Q I  d e f i n i t i o n  a n d 
classiﬁcation were widely accepted and 
immediately inﬂuential and were broadly 
applied to epidemiologic studies world-
wide. They also had their critics and their 
proponents for change, who presented 
cogent arguments for modiﬁcations.3,4 
Eriksen and Ingebretsen5 (this issue) 
now propose a change in the chronicity 
criterion of CKD stages 3 and 4. On the 
basis of analysis of the 10-year database 
of a cohort in a well-deﬁned geographic 
area served by one provider of universal 
health coverage, they show that chang-
ing the chronicity criterion to 6, 9, or 
12 months reduces the number of CKD 
patients relative to the 3-month criterion, 
with consequent diﬀering rates of pro-
gression to kidney failure or death.5 This 
retrospective, longitudinal study provides 
insight into the natural history of treated 
CKD in a homogeneous cohort, which 
the authors argue supports a change in 
the deﬁnition of CKD.
Actually, the classiﬁcation has been 
the subject of scrutiny by members of 
the original KDOQI workgroup and 
the Kidney Disease: Improving Global 
Outcomes (KDIGO) foundation. In 
2004, KDIGO convened a conference, 
attended by an international group of 
experts, that endorsed the KDOQI deﬁ-
nition and classiﬁcation but proposed 
incorporating the suﬃx D for individu-
als on maintenance dialysis, and clas-
sifying all kidney transplant recipients 
as having CKD and identifying them by 
the suﬃx T.6 In 2006, KDIGO convened 
another conference to examine new epi-
demiologic data and the need to reﬁne 
the classification to include clinical 
information. There was general agree-
ment (1) that CKD is a heterogeneous 
condition, whose clinical manifestations 
and course depend on and vary by cause, 
severity, rate of progression, and comor-
bid conditions; (2) that whereas addi-
tional clinical information is essential 
for the evaluation and management of 
individual cases, the potential beneﬁts 
of incorporating this information into 
the classification are outweighed by 
the disadvantages of adding increased 
complexity to the description of a het-
erogeneous condition; and (3) that the 
current classiﬁcation is clear, simple, and 
useful and does not need to be changed. 
There was strong concern that changes 
and additions would detract from main-
taining a simple system that has been 
accepted, and eﬀectively applied across 
disciplines, specialties, and countries.7
In evaluating the proposal of Erik-
sen and Ingebretsen,5 two fundamental 
issues need to be considered. First is the 
accuracy of the formulae to calculate 
eGFR (Modiﬁcation of Diet in Renal 
Disease (MDRD) or Cockcroft-Gault), 
and the diﬀering assays used to measure 
creatinine, from which eGFR is derived. 
The applicability of the formulae to vari-
ous populations and ethnic groups with 
diﬀerent body size and muscle mass, 
and consequently diﬀerent creatinine 
production, presents a new challenge 
as the classiﬁcation is applied to diverse 
populations. A worldwide eﬀort is under 
way to standardize the measurement of 
creatinine and develop modiﬁcations of 
the MDRD formula that would broaden 
its applicability to various populations 
and diﬀering groups.8 Like any other 
definition or classification, those of 
KDOQI are arbitrary, but until these 
methodological solutions are in place 
it would be hazardous to change them. 
Speciﬁcally pertinent to the proposal of 
Eriksen and Ingebretsen5 is the built-in 
variability (about 30%) of the MDRD 
formula used in their study. This vari-
ability, coupled with free access to treat-
ment and the racial homogeneity of 
their cohort, can account for some of 
their results. Importantly, whereas their 
Figure 1 | Conceptual model of the course and outcomes of chronic kidney disease. The ellipses represent progressive stages and 
consequences of chronic kidney disease (CKD). The first two open ellipses are antecedents and determinants of the increased risk for CKD. The 
next two ellipses are flagged for albuminuria and an estimated glomerular filtration rate of less than 60 ml/min/1.73 m2, the two determinants 
for the definition and detection of CKD. The larger ellipse at the top refers to complications that can develop at each stage of CKD (hypertension, 
anemia, mineral and bone disorders, cardiovascular disease) and their treatment (drug side effects). The gradually increasing thickness of 
the blue arrows connecting the ellipses represents the relative risk of the potential of kidney disease progression and its complications. The 
dotted arrows connecting the ellipses indicate the potential for improvements in albuminuria or glomerular filtration rate, due to treatment 
or variable natural history of the disease, which would affect staging. The thicker red arrows at the bottom indicate the greater risk of all-cause 
mortality, principally due to cardiovascular disease; their size relative to the other arrows reflects the greater risk of death at each stage than of 
progression to the next stage of CKD. GFR, glomerular filtration rate. Reprinted from ref. 2.
Normal Increased risk Damage Kidney failure Death↓GFR
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number of cases changed, the kidney 
disease persisted, albeit now classiﬁed 
at a diﬀerent stage.
Secondly, Eriksen and Ingebretsen’s 
proposal5 should be viewed in the 
broader context of the KDOQI guide-
lines, which, in addition to deﬁnition 
and classiﬁcation, proposed a model for 
developing a public-health approach to 
CKD.2 The data of Eriksen and Ingebret-
sen5 provide additional evidence in sup-
port of this model. As they show, whereas 
diﬀerent temporal criteria of chronicity 
changed the number of cases at each 
interval, patient death remained high in 
the new groupings.5 This supports the 
increasing evidence that the risk of death 
for CKD patients is several fold greater 
than the risk of moving up or down 
the stages of severity classification.9 
This relationship is not binary or asso-
ciated with any criterion of chronicity 
but is a continuum that increases at 
decreasing levels of eGFR independent 
of classiﬁcation.10 From a public-health 
perspective and for the clinical care 
of CKD patients, this is an extremely 
important message that outweighs other 
considerations, since a central tenet of 
any preventive eﬀort is early detection.
However, the original KDOQI pub-
lic-health model could be modified 
to incorporate accrued data, includ-
ing those of Eriksen and Ingebretsen5 
(Figure 1). In this simpliﬁed cartoon, 
the two principal determinants for the 
definition and detection of CKD are 
ﬂagged for albuminuria and an eGFR of 
less than 60 ml/min/1.73 m2. The ﬁve 
stages of CKD do not appear in the ﬁg-
ure. Rather, stages 1 and 2 are implicitly 
grouped together in the ellipse ﬂagged 
for albuminuria, and stages 3 and 4 
in the ellipse flagged for an eGFR of 
<60 ml/min/1.73 m2. The changes from 
the original of this ﬁgure2 are (1) the 
varying size of the arrows connecting 
the ellipses to reﬂect the relative risk 
of progression of CKD, and (2) incor-
poration of the arrows at the bottom 
to indicate the greater risk of all-cause 
mortality, principally from cardiovascu-
lar disease. The results of Eriksen and 
Ingebretsen5 provide strong evidence 
for the addition of the latter arrows, 
for the change in the size of the arrows 
connecting the ellipses, and for consid-
eration of making them bidirectional to 
indicate the changes in albuminuria or 
eGFR that reﬂect the course of a hetero-
geneous disease as a result of either its 
treatment or its variable natural history 
in diﬀerent populations—changes that 
would aﬀect the staging of patients over 
prolonged periods of observation of a 
chronic disease. Essentially, contrary to 
the implication of the direction of the 
arrows in the original model, not eve-
ryone with CKD shows a progressive 
course to kidney failure, as most cases 
at a certain stage never progress to the 
next stage, whereas some regress to a 
previous stage because of treatment, 
population-related natural history of 
CKD, or any other implicated determi-
nants of outcome.3–5
In conclusion, the KDOQI deﬁnition 
and classiﬁcation of CKD have stimu-
lated the generation of considerable 
new and important information but are 
arbitrary, need ongoing evaluation, and 
may well require modiﬁcation. In the 
meantime, the focus should remain on 
CKD as an ampliﬁer or modiﬁer of all-
cause mortality independent of staging.7 
It is essential that this simple message be 
maintained and transmitted to the pub-
lic, the profession, and health agencies.
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